Thursday, January 29, 2026

SOLAR PANELS

Physicists predict significant growth for cadmium telluride photovoltaics



A team of scientists analyzes challenges and proposes corresponding research goals in new solar energy research published in the peer-reviewed journal Joule.




University of Toledo

Dr. Michael Heben 

image: 

Dr. Michael Heben is a Distinguished University Professor and McMaster Chair and Director of the Wright Center for Photovoltaics Innovation and Commercialization.

view more 

Credit: The University of Toledo




A solar energy generation technology once considered limited in its potential is poised for significant growth in the United States.

That’s the conclusion of a team of scientists who analyzed the outlook for cadmium telluride photovoltaics in research published in the peer-reviewed journal Joule.

University of Toledo physicists including Dr. Michael Heben, a Distinguished University Professor and McMaster Chair and Director of the Wright Center for Photovoltaics Innovation and Commercialization, collaborated with partners at the U.S. Department of Energy’s National Laboratory of the Rockies, the Missouri University of Science and Technology, Colorado State University, Sivananthan Labs and First Solar under the umbrella of Department of Energy’s Cadmium Telluride Accelerator Consortium.

Their analysis presents challenges and corresponding research goals that the team of scientists believe will bring this technology to a manufacturing capacity of 100 gigawatts by 2030.

“There are a lot of advantages to cadmium telluride,” Heben said. “They perform better in hot and humid climates than the silicon photovoltaics that currently dominate the industry, and because their manufacturing process leverages domestic supply chains, they’re less sensitive to import restrictions while supporting national energy security.”

Cadmium telluride photovoltaics are a category of thin-film solar cells that have long shown promise as a reliable, low-cost and high-efficiency alternative to the crystalline silicon modules that currently dominate the global solar energy industry.

Cadmium telluride solar cells are the only other photovoltaics to be manufactured at the gigawatt scale, enjoying a particular niche in utility-scale deployment. But comparatively lower power conversion efficiencies and supply chain challenges have limited their share of the total solar power generation portfolio in the United States to approximately 16%.

UToledo is deeply engaged in the research and development of cadmium telluride solar cells through its Wright Center, where physicists’ groundbreaking work on this and other thin-film photovoltaic technologies in large part accounts for UToledo’s rank in the top quarter of global universities in materials science by U.S. News & World Report.

First Solar, the world’s largest manufacturer of cadmium telluride solar panels with a major presence in northwest Ohio, notably traces its roots to early work completed in campus labs in the 1980s.

The Joule research makes a case for significant growth potential in cadmium telluride photovoltaics, taking into account factors like economic policies favoring domestic manufacturing and technological advancements improving power conversion efficiency.

“Cadmium telluride has much more room to grow in performance compared to silicon,” Heben said. “The technology is very reliable and predictable, while the energy conversion efficiency is constantly moving upward.”

Scientists also address technological and supply chain advancements related to the element tellurium. They credit the technological advancements with enabling more efficient extraction and utilization of this mining byproduct, and they cite economic and industry data to demonstrate that its availability is not proving to be the limiting growth factor that manufacturers once predicted it would be.

It all adds up to a promising outlook for cadmium telluride photovoltaics.

“This research is essentially a roadmap for further growing and expanding this technology,” Heben said.

PRONOUNCED; NOOGING

‘Nudging’ both patients and providers boosts flu vaccine numbers




University of Pennsylvania School of Medicine




PHILADELPPHIA—Patients were 28 percent more likely to get a flu shot when they got a text message reminder and their primary care provider already had an order for the shot waiting, new research from the Perelman School of Medicine showed. The study was published in JAMA Internal Medicine

“This is important given the rise in vaccine hesitancy, which has resulted in a downward trend in flu vaccination that coincided with a high rate of hospitalization this flu season,” said the study’s lead author, Shivan Mehta, MD, MBA, MSHP, associate chief innovation officer at Penn Medicine. “Many nudge interventions directed to patients only on vaccinations have shown limited effectiveness in the United States, so we wanted to make sure that we addressed both sides of the exam room: the patient and the clinician.”   

The researchers believe these results might point to some strategies that could help boost how many people get the shot every year for an illness that has hospitalized up to 710,000 people each year since 2010—and killed as many as 52,000 Americans annually. 

Nudging versus standard care 

The study tested several forms of “nudging,” a behavioral science concept that means small tweaks that make the healthiest choices the easiest ones. Patients who were eligible for the vaccine received flu shot reminder texts (or automated voice recordings), had automatic orders for a flu shot waiting for their clinician to approve, and monthly personalized messages were sent to providers that compared their patients’ vaccination rates to their clinician peers. 

More than 52,000 people were randomly assigned to two groups: one that received all of the nudges or a “standard care” control group at either the University of Pennsylvania Health System or the University of Washington’s health system, UW Medicine The standard care team didn’t get any of the nudges and followed the usual path for getting a flu vaccine, which relies largely on the clinician remembering to offer the vaccine based on information in the electronic health records. Researchers found that almost 3,000 more people got flu shots when they were nudged than would have been expected if they got normal care. 

Why nudging patients and clinicians worked 

Mehta and his colleagues are encouraged by their findings, driven mainly by the importance of communication and trust. 

“We think the automatic order encouraged primary care physicians to have a conversation with their patients, and we know these clinicians still have a lot of trust from their communities,” said co-senior author Amol Navathe, MD, PhD, a professor of Medical Ethics and Health Policy, as well as a professor of Health Care Management in the Wharton School.  

The work continues at scale 

The team has replicated their work at Lancaster General Health in the University of Pennsylvania Health System, which serves a rural and suburban patient base that looks somewhat different than the study populations in this study drawn largely from Philadelphia and Seattle. They are still analyzing the results of this replication study.  

Since the work leverages existing tools in the electronic health record along with other available technologies but no additional staffing or human effort, it could be particularly attractive to health systems looking to augment their flu shot efforts.  

“Future interventions could be more successful by complementing the automated communication with clinical staff to engage with patients that are still hesitant, and integrating flu vaccine nudges with other interventions focused on preventive health, like cancer screening,” Mehta said.